Login to Your Account

Exelixis and Nektar gain ground, beat expectations

By Michael Fitzhugh
Staff Writer

Friday, May 1, 2015

Exelixis Inc. shares (NASDAQ:EXEL) climbed as much as 14 percent Friday on better-than-expected first quarter earnings and the hope that cabozantinib would blaze brighter in METEOR.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription